The global bladder cancer diagnostics market size was estimated to be USD 0.540 billion in 2023 and is expected to reach USD 1.29 billion by 2034 with a CAGR of 8.23% during the forecast period 2024-2034. The market will grow as a result of rising awareness and screening programs, rising incidence of bladder cancer, technological advancements in diagnostics, rising investments in research & development, and strategic alliances and collaborations.
Advancements in diagnostic technologies, including liquid biopsy, fluorescence in situ hybridization (FISH), and next-generation sequencing (NGS), are transforming the field of bladder cancer detection. These innovations provide enhanced accuracy, facilitate early detection, and offer non-invasive diagnostic alternatives, which are appealing to both healthcare providers and patients. For instance. The debut of the AssureMDxTM test, a test developed in a lab, was announced by VESICA HEALTH, INC. in May 2024. The firm is a well-known multi-omics liquid biopsy provider that aims to improve the management of patients with hematuria and can detect bladder cancer early. The purpose of this innovative test is to help physicians provide prompt and efficient care by enhancing the diagnostic capacities for bladder cancer.
By test type, the cystoscopy segment accounted for the highest revenue-grossing segment in the global bladder cancer diagnostics market in 2023 owing to the widespread use of cystoscopy as the gold standard for diagnosing bladder cancer, providing direct visualization of the bladder and allowing for biopsy procedures. For instance, Thermo Fisher Scientific Inc. declared in January 2023 that it had finalized the acquisition deal to purchase The Binding Site Group, a leading specialist diagnostics company worldwide. The acquisition will support the specialty diagnostics market's growth. Additionally, the imaging tests segment is predicted to grow at the fastest CAGR during the forecast period owing to the advancement of imaging technologies such as CT scans, MRIs, and ultrasound, which offer non-invasive and precise diagnostic capabilities, increasing their adoption.
By stage, the stage I and II segment accounted for the highest revenue-grossing segment in the global bladder cancer diagnostics market in 2023 owing to the high detection rates in these early stages, where patients often seek treatment due to visible symptoms like blood in urine, driving the need for diagnostic procedures. For instance, a urine-based biomarker developed by VESICA HEALTH, INC., a leading multi-omics liquid biopsy firm committed to enhancing the management of hematuria patients and the early identification of bladder cancer, was published in a peer-reviewed journal in March 2024. In patients with muscle-invasive bladder cancer (MIBC), the trial demonstrates the effectiveness of the noninvasive AssureMDxTM test in identifying urinary tract recurrence following bladder-sparing treatment. Additionally, the stage IV segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for advanced diagnostic techniques and monitoring tools in metastatic bladder cancer, where more complex assessments are required.
By cancer type, the transitional cell bladder cancer segment accounted for the highest revenue-grossing segment in the global bladder cancer diagnostics market in 2023 owing to the prevalence of transitional cell carcinoma (TCC), which is the most common type of bladder cancer, leading to higher diagnostic demand for this specific type. For instance, Bladder cancer patients in South Africa will now be able to receive blue light cystoscopy (BLC®) with Hexvix® thanks to a Named Patient Program (NPP) that was started in September 2024 by Photocure ASA (OSE: PHO), the Bladder Cancer Company, in collaboration with Equity Pharmaceuticals PTY Limited, a member of the Clinigen group. Additionally, the squamous cell bladder cancer segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising incidence of this rarer but aggressive cancer type, especially in regions with higher schistosomiasis infection rates, driving demand for specialized diagnostics.
By end-user, the hospitals segment accounted for the highest revenue-grossing segment in the global bladder cancer diagnostics market in 2023 owing to the availability of comprehensive diagnostic facilities, including advanced imaging and surgical procedures, and the ability to handle high patient volumes. For instance, Roche announced today, September 20, 2024, the addition of more than twenty cutting-edge artificial intelligence (AI) algorithms from eight new contributors to its digital pathology open ecosystem. Using cutting-edge AI technology, these strategic partnerships seek to assist scientists and pathologists in the study and detection of cancer. Additionally, the diagnostic imaging centers segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing preference for outpatient diagnostic services, which offer quicker access to imaging technologies and lower costs compared to hospitals.
North American region is anticipated for the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, high prevalence of bladder cancer, availability of advanced diagnostic technologies, and favorable reimbursement policies. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the growing healthcare investments, rising awareness of cancer screening programs, increasing incidence of bladder cancer, and expanding access to advanced diagnostic tools in emerging economies such as China and India. For instance, VESICA HEALTH, INC., a leading multi-omics liquid biopsy company dedicated to enhancing the management of hematuria patients and the early diagnosis of bladder cancer, is an exciting announcement that will be made in August 2024. A strong collection of internationally recognized professionals in bladder cancer make up the SAB. Their knowledge and experience will be useful in improving patient care at every stage of the process, from research to therapeutic tactics.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Advancements in diagnostic technologies, including liquid biopsy, fluorescence in situ hybridization (FISH), and next-generation sequencing (NGS), are transforming the field of bladder cancer detection. These innovations provide enhanced accuracy, facilitate early detection, and offer non-invasive diagnostic alternatives, which are appealing to both healthcare providers and patients. For instance. The debut of the AssureMDxTM test, a test developed in a lab, was announced by VESICA HEALTH, INC. in May 2024. The firm is a well-known multi-omics liquid biopsy provider that aims to improve the management of patients with hematuria and can detect bladder cancer early. The purpose of this innovative test is to help physicians provide prompt and efficient care by enhancing the diagnostic capacities for bladder cancer.
By test type, the cystoscopy segment accounted for the highest revenue-grossing segment in the global bladder cancer diagnostics market in 2023 owing to the widespread use of cystoscopy as the gold standard for diagnosing bladder cancer, providing direct visualization of the bladder and allowing for biopsy procedures. For instance, Thermo Fisher Scientific Inc. declared in January 2023 that it had finalized the acquisition deal to purchase The Binding Site Group, a leading specialist diagnostics company worldwide. The acquisition will support the specialty diagnostics market's growth. Additionally, the imaging tests segment is predicted to grow at the fastest CAGR during the forecast period owing to the advancement of imaging technologies such as CT scans, MRIs, and ultrasound, which offer non-invasive and precise diagnostic capabilities, increasing their adoption.
By stage, the stage I and II segment accounted for the highest revenue-grossing segment in the global bladder cancer diagnostics market in 2023 owing to the high detection rates in these early stages, where patients often seek treatment due to visible symptoms like blood in urine, driving the need for diagnostic procedures. For instance, a urine-based biomarker developed by VESICA HEALTH, INC., a leading multi-omics liquid biopsy firm committed to enhancing the management of hematuria patients and the early identification of bladder cancer, was published in a peer-reviewed journal in March 2024. In patients with muscle-invasive bladder cancer (MIBC), the trial demonstrates the effectiveness of the noninvasive AssureMDxTM test in identifying urinary tract recurrence following bladder-sparing treatment. Additionally, the stage IV segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for advanced diagnostic techniques and monitoring tools in metastatic bladder cancer, where more complex assessments are required.
By cancer type, the transitional cell bladder cancer segment accounted for the highest revenue-grossing segment in the global bladder cancer diagnostics market in 2023 owing to the prevalence of transitional cell carcinoma (TCC), which is the most common type of bladder cancer, leading to higher diagnostic demand for this specific type. For instance, Bladder cancer patients in South Africa will now be able to receive blue light cystoscopy (BLC®) with Hexvix® thanks to a Named Patient Program (NPP) that was started in September 2024 by Photocure ASA (OSE: PHO), the Bladder Cancer Company, in collaboration with Equity Pharmaceuticals PTY Limited, a member of the Clinigen group. Additionally, the squamous cell bladder cancer segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising incidence of this rarer but aggressive cancer type, especially in regions with higher schistosomiasis infection rates, driving demand for specialized diagnostics.
By end-user, the hospitals segment accounted for the highest revenue-grossing segment in the global bladder cancer diagnostics market in 2023 owing to the availability of comprehensive diagnostic facilities, including advanced imaging and surgical procedures, and the ability to handle high patient volumes. For instance, Roche announced today, September 20, 2024, the addition of more than twenty cutting-edge artificial intelligence (AI) algorithms from eight new contributors to its digital pathology open ecosystem. Using cutting-edge AI technology, these strategic partnerships seek to assist scientists and pathologists in the study and detection of cancer. Additionally, the diagnostic imaging centers segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing preference for outpatient diagnostic services, which offer quicker access to imaging technologies and lower costs compared to hospitals.
North American region is anticipated for the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, high prevalence of bladder cancer, availability of advanced diagnostic technologies, and favorable reimbursement policies. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the growing healthcare investments, rising awareness of cancer screening programs, increasing incidence of bladder cancer, and expanding access to advanced diagnostic tools in emerging economies such as China and India. For instance, VESICA HEALTH, INC., a leading multi-omics liquid biopsy company dedicated to enhancing the management of hematuria patients and the early diagnosis of bladder cancer, is an exciting announcement that will be made in August 2024. A strong collection of internationally recognized professionals in bladder cancer make up the SAB. Their knowledge and experience will be useful in improving patient care at every stage of the process, from research to therapeutic tactics.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Test Type, Stage, Cancer Type, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Bladder Cancer Diagnostics Market Report 2023 - 2034
Bladder Cancer Diagnostics Market Analysis & Forecast by Test Type 2023 - 2034 (Revenue USD Bn)
- Cystoscopy
- Urine Lab Test
- Biopsy
- Imaging Test
- Others
Bladder Cancer Diagnostics Market Analysis & Forecast by Stage 2023 - 2034 (Revenue USD Bn)
- Stage I
- Stage II
- Stage III
- Stage IV
Bladder Cancer Diagnostics Market Analysis & Forecast by Cancer Type 2023 - 2034 (Revenue USD Bn)
- Transitional Cell Bladder Cancer
- Squamous Cell Bladder Cancer
- Other Cancer Types
Bladder Cancer Diagnostics Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Hospital
- Diagnostic Imaging Centers
- Cancer Research Institutes
- Diagnostic Laboratories
- Others
Bladder Cancer Diagnostics Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Bladder Cancer Diagnostics Market: Test Type Estimates & Trend Analysis
8. Bladder Cancer Diagnostics Market: Stage Estimates & Trend Analysis
9. Bladder Cancer Diagnostics Market: Cancer Type Estimates & Trend Analysis
10. Bladder Cancer Diagnostics Market: End-User Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Bladder Cancer Diagnostics Market
13. Europe Global Bladder Cancer Diagnostics Market
14. Asia Pacific Global Bladder Cancer Diagnostics Market
15. Latin America Global Bladder Cancer Diagnostics Market
16. MEA Global Bladder Cancer Diagnostics Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Abbott Laboratories
- Roche Diagnostics
- Siemens Healthineers
- Thermo Fisher Scientific
- F. Hoffmann-La Roche AG
- Hologic Inc.
- Quest Diagnostics
- Agilent Technologies
- Illumina Inc.
- Cleveland Diagnostics Inc.
- BioTechne Corporation
- MDxHealth SA
- Bristol-Myers Squibb Company
- CureMetrix
- NantHealth Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | December 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 0.54 Billion |
| Forecasted Market Value ( USD | $ 1.29 Billion |
| Compound Annual Growth Rate | 8.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
